Identification of novel biomarkers for treatment monitoring in canine leishmaniosis by high-resolution quantitative proteomic analysis
dc.contributor.author | Martinez, Subiela Silvia | |
dc.contributor.author | Horvatic, Anita | |
dc.contributor.author | Escribano, Damian | |
dc.contributor.author | Pardo, Luis Marin | |
dc.contributor.author | Mrljak, Vladimir | |
dc.contributor.author | Burchmore, Richard | |
dc.contributor.author | Ceron, Jose J. | |
dc.contributor.buuauthor | Kocatürk, Meriç | |
dc.contributor.buuauthor | Yılmaz, Zeki | |
dc.contributor.department | Uludağ Üniversitesi/Veteriner Fakültesi/İç Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0001-9836-0749 | tr_TR |
dc.contributor.researcherid | V-5578-2017 | tr_TR |
dc.contributor.scopusid | 36437200800 | tr_TR |
dc.contributor.scopusid | 35944810500 | tr_TR |
dc.date.accessioned | 2022-12-23T11:01:32Z | |
dc.date.available | 2022-12-23T11:01:32Z | |
dc.date.issued | 2017-08-08 | |
dc.description.abstract | The objective of this study was to use the Tandem Mass Tag (TMT) isobaric label-based proteomic approach, in order to identify new potential biomarkers for the treatment monitoring of canine leishmaniosis that could not be identified by the use of gel-based techniques. For this purpose serum samples were obtained from 5 clinically diseased dogs before and one month after the treatment of canine leishmaniosis. The non-depleted serum samples were subjected to reduction, alkylation and trypsin digestion, and the resulting peptides were labeled using 6-plex TMT reagents. To obtain information about protein identities and relative quantification, liquid chromatography-MS analysis of multiplexed TMT-labeled peptides was employed. This gel-free, label-based quantitative proteomic approach enabled identification of 117 canine proteins. Among these, 23 showed significant difference (p < 0.05) in expression (two downregulated and 21 upregulated ranging from 1.25 to 2.5 fold change). Comparison of gel-free TMT-based quantification and a gel-based approach previously applied to the same samples resulted in the identification of some common markers (Apo-A1, vitamin D binding protein and RBP4). However, 20 additional differentially represented proteins were highlighted by the gel-free approach, 13 of which have not been previously reported in canine leishmaniosis. In conclusion, the TMT-based proteomic approach allowed identification of new serum proteins that significantly change in concentration after canine leishmaniosis treatment. These proteins are involved in various physiopathological processes such as inflammatory, coagulation or defense mechanisms, and could potentially be suitable biomarkers for treatment monitoring of this parasitic disease. | en_US |
dc.description.sponsorship | Fundacion Seneca - 19894/GERM/15 | en_US |
dc.description.sponsorship | ERA Chair initiative (VetMedZg) - 621394 | en_US |
dc.description.sponsorship | Robles Chillida foundation | en_US |
dc.description.sponsorship | European Commission European Commission Joint Research Centre | en_US |
dc.identifier.citation | Martinize, S. S. vd. (2017). ''Identification of novel biomarkers for treatment monitoring in canine leishmaniosis by high-resolution quantitative proteomic analysis''. Veterinary Immunology and Immunopathology, 191, 60-67. | en_US |
dc.identifier.endpage | 67 | tr_TR |
dc.identifier.issn | https://www.sciencedirect.com/science/article/pii/S0165242717301575 | |
dc.identifier.issn | 0165-2427 | |
dc.identifier.pubmed | 28895868 | tr_TR |
dc.identifier.scopus | 2-s2.0-85028374669 | tr_TR |
dc.identifier.startpage | 60 | tr_TR |
dc.identifier.uri | https://doi.org/10.1016/j.vetimm.2017.08.004 | |
dc.identifier.uri | 1873-2534 | |
dc.identifier.uri | http://hdl.handle.net/11452/30065 | |
dc.identifier.volume | 191 | tr_TR |
dc.identifier.wos | 000412254100009 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.journal | Veterinary Immunology and Immunopathology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.relation.tubitak | TOVAG-2130032 | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Immunology | en_US |
dc.subject | Veterinary sciences | en_US |
dc.subject | Biomarkers | en_US |
dc.subject | Dog | en_US |
dc.subject | Gel free proteomics | en_US |
dc.subject | Leishmaniosis | en_US |
dc.subject | Treatment | en_US |
dc.subject | Alpha-trypsin inhibitor | en_US |
dc.subject | Mass-spectrometry | en_US |
dc.subject | Membrane-proteins | en_US |
dc.subject | Kinin system | en_US |
dc.subject | Plasma | en_US |
dc.subject | Dogs | en_US |
dc.subject | Complex | en_US |
dc.subject | Promastigotes | en_US |
dc.subject | Inflammation | en_US |
dc.subject | Disease | en_US |
dc.subject.emtree | Allopurinol | en_US |
dc.subject.emtree | Apolipoprotein A1 | en_US |
dc.subject.emtree | Beta 2 glycoprotein 1 precursor | en_US |
dc.subject.emtree | Beta2 glycoprotein 1 | en_US |
dc.subject.emtree | Biological marker | en_US |
dc.subject.emtree | Fibronectin | en_US |
dc.subject.emtree | Fibronectin isoform X1 | en_US |
dc.subject.emtree | Inter alpha trypsin inhibitor | en_US |
dc.subject.emtree | Inter alpha trypsin inhibitor heavy chain H1 isoform X1 | en_US |
dc.subject.emtree | Inter alpha trypsin inhibitor heavy chain H2 | en_US |
dc.subject.emtree | Inter alpha trypsin inhibitor heavy chain H4 isoform X1 | en_US |
dc.subject.emtree | Kininogen 1 isoform X1 | en_US |
dc.subject.emtree | Kininogen 1 isoform X2 | en_US |
dc.subject.emtree | Mmyosin VI | en_US |
dc.subject.emtree | Plasminogen | en_US |
dc.subject.emtree | Plasminogen precursor | en_US |
dc.subject.emtree | Retinol binding protein 4 | en_US |
dc.subject.emtree | Serotransferrin | en_US |
dc.subject.emtree | Serum albumin | en_US |
dc.subject.emtree | Serum albumin isoform X1 | en_US |
dc.subject.emtree | Serum albumin precursor | en_US |
dc.subject.emtree | Spectrin | en_US |
dc.subject.emtree | Spectrin beta chain erythrocytic | en_US |
dc.subject.emtree | Spectrin beta chain non erythrocytic 1 isoform X1 | en_US |
dc.subject.emtree | Transferrin | en_US |
dc.subject.emtree | Trypsin | en_US |
dc.subject.emtree | Uunclassified drug | en_US |
dc.subject.emtree | Uunconventional myosin VI isoform X1 | en_US |
dc.subject.emtree | Unindexed drug | en_US |
dc.subject.emtree | Vitamin D binding protein | en_US |
dc.subject.emtree | Acute phase protein | en_US |
dc.subject.emtree | Allopurinol | en_US |
dc.subject.emtree | Antiprotozoal agent | en_US |
dc.subject.emtree | Biological marker | en_US |
dc.subject.emtree | Ferritin | en_US |
dc.subject.emtree | Meglumine | en_US |
dc.subject.emtree | Meglumine antimoniate | en_US |
dc.subject.emtree | Organometallic compound | en_US |
dc.subject.emtree | Serum globulin | en_US |
dc.subject.emtree | Alkylation | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Blood sampling | en_US |
dc.subject.emtree | Comparative study | en_US |
dc.subject.emtree | Dog disease | en_US |
dc.subject.emtree | Down regulation | en_US |
dc.subject.emtree | Drug monitoring | en_US |
dc.subject.emtree | Enzyme metabolism | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gene expression profiling | en_US |
dc.subject.emtree | Gene ontology | en_US |
dc.subject.emtree | Leishmaniasis | en_US |
dc.subject.emtree | Liquid chromatography-mass spectrometry | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Protein analysis | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Protein folding | en_US |
dc.subject.emtree | Proteomics | en_US |
dc.subject.emtree | Quantitative analysis | en_US |
dc.subject.emtree | Upregulation | en_US |
dc.subject.emtree | Animal | en_US |
dc.subject.emtree | Blood | en_US |
dc.subject.emtree | Dog | en_US |
dc.subject.emtree | Dog disease | en_US |
dc.subject.emtree | Leishmaniasis | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Parasitology | en_US |
dc.subject.emtree | Procedures | en_US |
dc.subject.emtree | Proteomics | en_US |
dc.subject.emtree | Veterinary | en_US |
dc.subject.mesh | Acute-phase proteins | en_US |
dc.subject.mesh | Allopurinol | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antiprotozoal agents | en_US |
dc.subject.mesh | Biomarkers | en_US |
dc.subject.mesh | Dog diseases | en_US |
dc.subject.mesh | Dogs | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Ferritins | en_US |
dc.subject.mesh | Leishmaniasis | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Meglumine | en_US |
dc.subject.mesh | Organometallic compounds | en_US |
dc.subject.mesh | Proteomics | en_US |
dc.subject.mesh | Serum globulins | en_US |
dc.subject.scopus | Leishmania Infantum; Dog; Psychodidae | en_US |
dc.subject.wos | Immunology | en_US |
dc.subject.wos | Veterinary sciences | en_US |
dc.title | Identification of novel biomarkers for treatment monitoring in canine leishmaniosis by high-resolution quantitative proteomic analysis | en_US |
dc.type | Article | |
dc.wos.quartile | Q4 (Immunology) | en_US |
dc.wos.quartile | Q1 (Veterinary sciences) | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: